GLP-1 Agonists Show Potential in Reducing Alcohol Intake by Altering Pharmacokinetics and Perceived Intoxication

The intersection of metabolic health and addiction science has reached a significant milestone as new evidence suggests that the class of medications currently revolutionizing weight loss and diabetes management—glucagon-like peptide-1 (GLP-1) receptor agonists—may also serve as a powerful tool in the fight against alcohol use disorder. A burgeoning body of research, highlighted by a recent study from the Fralin Biomedical Research Institute at VTC, indicates that medications such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) may fundamentally alter how the human body processes alcohol, leading to a natural reduction in consumption.

The study, published this month in the peer-reviewed journal Scientific Reports, provides a physiological explanation for a phenomenon that has been circulating in patient anecdotes and social media forums for several years: people taking these drugs simply lose interest in drinking. Researchers found that GLP-1 agonists appear to slow the rate at which alcohol enters the bloodstream, thereby delaying its psychoactive effects on the brain and reducing the "reward" sensation typically associated with consumption.

The Science of Speed: Why Absorption Matters

At the heart of the study is the concept of pharmacokinetics—the way the body moves a chemical through its systems. Alex DiFeliceantonio, an assistant professor and interim co-director of the Fralin Biomedical Research Institute’s Center for Health Behaviors Research, notes that the speed of delivery is a critical factor in the addictive potential of any substance.

"People who drink know there’s a difference between nursing a glass of wine and downing a shot of whiskey," DiFeliceantonio explained. While a standard serving of wine, beer, or spirits contains roughly 0.6 ounces of pure alcohol, the biological impact depends heavily on how quickly that alcohol reaches the brain. A shot of spirits causes a rapid spike in blood-alcohol levels, which the brain perceives as a more intense "hit."

The study suggests that GLP-1 medications interfere with this process by slowing gastric emptying—the process by which the stomach sends its contents into the small intestine. Because the small intestine is where the majority of alcohol is absorbed into the blood, delaying this transition means the alcohol enters the system at a more gradual pace.

"Faster-acting drugs have a higher abuse potential," DiFeliceantonio said. "They have a different impact on the brain. So if GLP-1s slow alcohol entering the bloodstream, they could reduce the effects of alcohol and help people drink less."

Methodology: Testing the "Drunk" Factor

To test this hypothesis, the research team conducted a controlled pilot study involving twenty adults. Each participant had a body mass index (BMI) of 30 or higher, meeting the clinical definition for obesity. The group was split evenly: ten participants were currently prescribed a GLP-1 medication (such as semaglutide, tirzepatide, or liraglutide), while the other ten served as a control group and were not taking any such medication.

The experimental protocol was rigorous. Participants were required to fast before their session to ensure a baseline state. Upon arrival, they were provided with a standardized snack bar to ensure that stomach contents were consistent across the board, minimizing variables that could affect alcohol absorption. Researchers then established baseline metrics, measuring blood pressure, pulse, breath alcohol concentration, and blood glucose levels.

Ninety minutes after the snack, participants were served a standard alcoholic drink, which they were required to finish within a 10-minute window. Over the following hour, the researchers monitored the participants closely, taking measurements and asking them to self-report their perceived levels of intoxication, cravings, and appetite. One of the central metrics was a subjective "drunk scale" ranging from zero to ten.

The results were consistent and statistically significant. Despite consuming the exact same amount of alcohol relative to their body mass, the participants on GLP-1 medications reached lower peak blood-alcohol concentrations than the control group. Furthermore, their subjective experience was notably different; they consistently reported feeling less intoxicated and experienced fewer cravings for a second drink.

A Legacy of Discovery: The Research Timeline

The origins of this study can be traced back to a faculty retreat at the Fralin Biomedical Research Institute, where scientists began discussing the "side effects" being reported by patients on Ozempic. The project was spearheaded by the late Warren Bickel, a renowned professor and director of the Addiction Recovery Research Center. Bickel, who passed away in 2024, was a pioneer in the study of "delay discounting"—the psychological process by which individuals choose smaller, immediate rewards (like the buzz from a drink) over larger, delayed rewards (like long-term health).

The study was also heavily influenced by "digital phenotyping"—the analysis of social media trends. Fatima Quddos, a graduate researcher in Bickel’s lab and the first author of the study, had previously analyzed thousands of posts on Reddit. In those forums, users frequently reported a "disinterest" in alcohol after starting GLP-1 treatments, with some describing the experience as "losing the urge" to drink entirely.

"His guidance shaped every stage of this research—from the initial idea to its final form—and his passion for scientific discovery continues to inspire me every day," said Quddos, who recently earned her doctorate. "Bickel’s work had long focused on what happens when you delay rewards, so we asked, ‘What if GLP-1s affect how the body handles alcohol?’"

Contextualizing the Public Health Crisis

The potential for GLP-1s to treat alcohol use disorder (AUD) comes at a critical time for public health. According to the Centers for Disease Control and Prevention (CDC), more than half of U.S. adults consume alcohol, and approximately one in ten suffers from some form of AUD. The toll of chronic heavy drinking is immense, contributing to a spike in high blood pressure, heart disease, liver cirrhosis, and various forms of cancer.

Earlier this year, U.S. Surgeon General Vivek Murthy issued a stark reminder of these dangers, identifying alcohol consumption as the nation’s third leading preventable cause of cancer, trailing only tobacco use and obesity. Despite the scale of the problem, current pharmaceutical interventions for AUD are limited.

The primary medications currently approved by the FDA—naltrexone and acamprosate—work largely by targeting the central nervous system to reduce cravings or block the euphoric effects of alcohol. However, these drugs have varying levels of efficacy and are often underutilized.

"Our preliminary data suggest that GLP-1s suppress intake through a different mechanism," DiFeliceantonio said. By slowing the physical absorption of the substance and potentially interacting with reward pathways in the brain that overlap with hunger and satiety, GLP-1s offer a multi-pronged approach to addiction that current medications do not.

Implications for Future Treatment and Policy

While the Fralin Biomedical Research Institute study was a pilot, its findings have paved the way for larger, long-term clinical trials. The researchers emphasized that because GLP-1 medications are already FDA-approved for other conditions and have a well-documented safety profile, the path to repurposing them for AUD could be faster than developing a new drug from scratch.

"He was always asking, ‘How do we help people the fastest?’" DiFeliceantonio recalled of Bickel’s philosophy. "Using a drug that’s already shown to be safe to help people reduce drinking could be a way to get people help fast."

However, there are still many questions to be answered. Researchers need to determine the optimal dosage for treating addiction, which may differ from the dosages used for weight loss or diabetes. There is also the question of "rebound" effects—whether cravings return with greater intensity if the medication is discontinued. Furthermore, the high cost and current supply shortages of drugs like semaglutide remain significant barriers to widespread access for addiction treatment.

Analysis: A Paradigm Shift in Addiction Medicine

The shift toward using metabolic drugs for behavioral disorders represents a significant paradigm shift in medicine. It suggests that the biological systems governing hunger, glucose regulation, and chemical dependency are more deeply intertwined than previously understood. If a single hormone (GLP-1) can regulate the desire for both food and alcohol, it opens the door to a more holistic understanding of compulsive behaviors.

From a clinical perspective, the fact that participants in the study felt "less drunk" is a double-edged sword. While it might lead some to drink more to achieve the desired effect, the overall trend seen in both this study and anecdotal reports suggests the opposite: when the "reward" is delayed or muted, the motivation to consume the substance diminishes.

As the scientific community awaits the results of larger-scale trials, the work of Quddos, DiFeliceantonio, and the late Professor Bickel stands as a testament to the power of interdisciplinary research.

"As a recent graduate, I’m deeply inspired by the potential this research holds—not only for advancing our scientific understanding but also for paving the way toward future therapies," Quddos said. "The possibility of offering new hope to individuals struggling with addiction is what makes this work so meaningful."

With alcohol-related deaths on the rise globally, the repurposing of GLP-1 agonists could provide a much-needed lifeline for millions, transforming a class of "diet drugs" into a cornerstone of addiction recovery and public health.